Prof. Kalavrouziotis

Edwards Lifesciences at EACTS 2022: State of the art in the treatment of aortic valve regurgitation in young patients

Prof. Augusto D’Onofrio

MVT Aortic 2022, vol.1

– Not only about hemodynamics, this lecture provides comparisons among three bioprostheses

– Similar clinical outcomes, better hemodynamic results, and shorter ICU stays for rapid deployment valves… but newer bioprosthesis tissue technology may raise the bar even higher

Prof. Bart Meuris

MVT Aortic 2022, vol.1

-Cosmesis vs clinical benefit? Cross-clamp times? Extra costs? Have you thought about these aspects before?

-What about less pain? Less blood loss? Shorter ICU stays? Lower rates of atrial fibrillation? Remember, there are always pros and cons.

-If combined procedures are necessary, minimally invasive can be a choice in experienced centers